The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10740 malaria professionals are enjoying the free benefits of MalariaWorld today

falciparum malaria

Open Access | Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine

October 15, 2010 - 07:44 -- Kabogo Ndegwa
Author(s): 
Ali S, Najmi MH, Tarning J, Lindegardh N
Reference: 
Malaria Journal 2010, 9:275 (11 October 2010)

The overall pharmacokinetic properties of artemether and dihydroartemisinin in healthy Pakistani subjects are comparable to healthy subjects and patients from other populations.

Country: 
Medical Condition: 
Medical Treatment: 

Open Access | Different mutation patterns of Plasmodium falciparum among patients in Jimma University Hospital, Ethiopia

August 10, 2010 - 08:10 -- Kabogo Ndegwa
Author(s): 
Eshetu T, Berens-Riha N, Fekadu S, Tadesse Z, Gurkov R, Holscher M, Loscher T, Barreto Miranda I
Reference: 
Malaria Journal 2010, 9:226 (7 August 2010)

The prevalence of mutations was in accordance with the expected patterns considering recent drug regiments. The broad introduction of AL and the cessation of former drug regimens might probably change the current distribution of polymorphisms, possibly leading to decreased sensitivity to AL in future.

Country: 
Medical Condition: 
Medical Treatment: 

Open Access | An Open-Label, Randomised Study of Dihydroartemisinin-Piperaquine Versus Artesunate-Mefloquine for Falciparum Malaria in Asia

August 5, 2010 - 12:39 -- Kabogo Ndegwa
Author(s): 
Neena Valecha, Aung Pyae Phyo, Sasithon Pukittayakamee, et al
Reference: 
PLoS ONE 5(7): e11880

DHA/PQP was a highly efficacious drug for P. falciparum malaria in areas where multidrug parasites are prevalent. The DHA/PQP combination can play an important role in the first-line treatment of uncomplicated falciparum malaria.

Continent: 
Medical Condition: 
Medical Treatment: 

Fixed artesunate-amodiaquine combined pre-formulation study for the treatment of malaria

July 20, 2010 - 08:07 -- Kabogo Ndegwa
Tags: 
Author(s): 
T Kauss, F Fawaz, M Guyot, AM Lagueny, I dos Santos, F Bonini, P Olliaro, A Caminiti, P Millet
Reference: 
International Journal of Pharmaceutics, Volume 395, Issues 1-2, 16 August 2010, Pages 198-204

Artemisinin-based combination therapies, including artesunate (AS) + amodiaquine (AQ), are the currently recommended first-line treatment of uncomplicated falciparum malaria. Fixed-dose co-formulations offer logistic and adherence advantages.

Medical Condition: 
Medical Treatment: 

On the Cytoadhesion of Plasmodium vivax-Infected Erythrocytes

July 16, 2010 - 14:17 -- Kabogo Ndegwa
Author(s): 
BO Carvalho, SC Lopes, FT Costa, et al.
Reference: 
The Journal of Infectious Diseases 2010;202: 638–647

These observations prompt a modification of the current paradigms of the pathogenesis of malaria and clear the way to investigate the pathophysiology of P. vivax infections.

High chloroquine treatment failure rates and predominance of mutant genotypes associated with chloroquine and antifolate resistance among falciparum malaria patients from the island of Car Nicobar, India

May 13, 2010 - 13:17 -- Patrick Sampao
Author(s): 
Manoj K. Das1, Vanshika Lumb, Pooja Mittra, Shiv S. Singh, Aditya P. Dash and Yagya D. Sharma
Reference: 
Journal of Antimicrobial Chemotherapy 2010 65(6):1258-1261

There is a predominance of chloroquine- and antifolate-resistant P. falciparum malaria in Car Nicobar, requiring an alternative antimalarial drug treatment policy, such as implementation of artesunate combination therapy (ACT), for this island.

Region: 
City: 
Medical Condition: 
Medical Treatment: 

Open Access | Increased Asymmetric Dimethylarginine in Severe Falciparum Malaria: Association with Impaired Nitric Oxide Bioavailability and Fatal Outcome

April 27, 2010 - 13:44 -- Kabogo Ndegwa
Author(s): 
Tsin W. Yeo, Daniel A. Lampah, Nicholas M. Anstey,. et al
Reference: 
PLoS Pathog 6(4): e1000868

Asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), is a predictor of mortality in critical illness. Severe malaria (SM) is associated with decreased NO bioavailability, but the contribution of ADMA to the pathogenesis of impaired NO bioavailability and adverse outcomes in malaria is unknown.

Person: 
Medical Condition: 

Open Access | Research: Randomized controlled trial of artesunate or artemether in Vietnamese adults with severe falciparum malaria

April 16, 2010 - 08:29 -- Kabogo Ndegwa
Author(s): 
Phu NH, Tuan PQ, Day N, Mai NT, Chau TT, Chuong LV, Sinh DX, White NJ, Farrar J, Tran HT
Reference: 
Malaria Journal 2010, 9:97 (15 April 2010)

Both artemether and artesunate have been shown to be superior to quinine for the treatment of severe falciparum malaria in Southeast Asian adults, although the magnitude of the superiority has been greater for artesunate than artemether. These two artemisinin derivatives had not been compared in a randomized trial.

Technology: 
Medical Condition: 
Medical Treatment: 

Open Access | Research: Determining utility values related to malaria and malaria chemoprophylaxis

April 13, 2010 - 09:21 -- Kabogo Ndegwa
Author(s): 
McCarthy AE, Coyle D
Reference: 
Malaria Journal 2010, 9:92 (9 April 2010)

The general public (potential travellers), were more tolerant of taking prophylaxis if associated with no or mild AEs and least tolerant of mild sequelae from malaria and severe drug related events. The rating value reported for taking no prophylaxis was quite variable.

Person: 

Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon

April 8, 2010 - 12:50 -- Kabogo Ndegwa
Author(s): 
MK Bouyou-Akotet, M Ramharter, EB Ngoungou, MM Mamfoumbi, MP Mihindou, MA Missinou, F Kurth, S Bélard, ST Agnandji, S Issifou, JL Heidecker, S Trapp, PG Kremsner, M Kombila
Reference: 
Wiener Klinische Wochenschrift, Volume 122, Numbers 5-6 / March, 2010 Pages 173-178

Pediatric drug formulations of artemisinin combination therapies are urgently needed for improving the treatment of children suffering from uncomplicated malaria. The aim of this clinical trial was to evaluate the efficacy, safety and tolerability of a novel pediatric fixed-dose granule formulation of artesunate-mefloquine and a new co-blister tablet formulation.

Person: 
Country: 
Medical Condition: 
Medical Treatment: 

Pages

Subscribe to RSS - falciparum malaria